-transparent.png){kind=logo}
Based on the vasodilator properties of calcium antagonists, verapamil was recently introduced into the treatment of arterial hypertension. The present study was undertaken to examine the long-term efficacy of this drug in mild and moderate hypertension. In 82 patients with uncontrolled primary or renal hypertension, verapamil was used either alone or in combination with other drugs. In six cases verapamil was withdrawn because of side effects. In the remaining patients a normal average blood pressure was achieved within 7.8 +/- 1.2 weeks of treatment with doses not exceeding 400 mg/day. This effect was maintained for up to 4 years of treatment, although tolerance seemed to develop in about 10% of the patients. In view of this good response and minimal side effects, it is concluded that verapamil is an effective addition to the antihypertensive arsenal.
I Wigler, and
G Peer, and
G Soferman, and
M Blum, and
A Aviram
January 1982,
Clinical and experimental pharmacology & physiology. Supplement,
I Wigler, and
G Peer, and
G Soferman, and
M Blum, and
A Aviram
December 1988,
Angiology,
I Wigler, and
G Peer, and
G Soferman, and
M Blum, and
A Aviram
February 1986,
The American journal of cardiology,
I Wigler, and
G Peer, and
G Soferman, and
M Blum, and
A Aviram
December 1982,
Minerva cardioangiologica,
I Wigler, and
G Peer, and
G Soferman, and
M Blum, and
A Aviram
November 1979,
La Nouvelle presse medicale,
I Wigler, and
G Peer, and
G Soferman, and
M Blum, and
A Aviram
September 1974,
Minerva cardioangiologica,
I Wigler, and
G Peer, and
G Soferman, and
M Blum, and
A Aviram
January 1988,
Clinical therapeutics,
I Wigler, and
G Peer, and
G Soferman, and
M Blum, and
A Aviram
August 1965,
Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete,
I Wigler, and
G Peer, and
G Soferman, and
M Blum, and
A Aviram
September 1970,
Arzneimittel-Forschung,
I Wigler, and
G Peer, and
G Soferman, and
M Blum, and
A Aviram
June 1988,
Medicina clinica,
